TY - JOUR
T1 - Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality
AU - Budhraja, Anshul
AU - Basu, Anubhav
AU - Gheware, Atish
AU - Abhilash, Dasari
AU - Rajagopala, Seesandra
AU - Pakala, Suman
AU - Sumit, Madhuresh
AU - Ray, Animesh
AU - Subramaniam, Arulselvi
AU - Mathur, Purva
AU - Nambirajan, Aruna
AU - Kumar, Sachin
AU - Gupta, Ritu
AU - Wig, Naveet
AU - Trikha, Anjan
AU - Guleria, Randeep
AU - Sarkar, Chitra
AU - Gupta, Ishaan
AU - Jain, Deepali
N1 - Publisher Copyright:
© 2022.
PY - 2022/5
Y1 - 2022/5
N2 - To elucidate the molecular mechanisms that manifest lung abnormalities during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, we performed whole-transcriptome sequencing of lung autopsies from 31 patients with severe COVID-19 and ten uninfected controls. Using metatranscriptomics, we identified the existence of two distinct molecular signatures of lethal COVID-19. The dominant ‘classical’ signature (n=23) showed upregulation of the unfolded protein response, steroid biosynthesis and complement activation, supported by massive metabolic reprogramming leading to characteristic lung damage. The rarer signature (n=8) that potentially represents ‘cytokine release syndrome’ (CRS) showed upregulation of cytokines such as IL1 and CCL19, but absence of complement activation. We found that a majority of patients cleared SARS-CoV-2 infection, but they suffered from acute dysbiosis with characteristic enrichment of opportunistic pathogens such as Staphylococcus cohnii in ‘classical’ patients and Pasteurella multocida in CRS patients. Our results suggest two distinct models of lung pathology in severe COVID-19 patients, which can be identified through complement activation, presence of specific cytokines and characteristic microbiome. These findings can be used to design personalized therapy using in silico identified drug molecules or in mitigating specific secondary infections.
AB - To elucidate the molecular mechanisms that manifest lung abnormalities during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, we performed whole-transcriptome sequencing of lung autopsies from 31 patients with severe COVID-19 and ten uninfected controls. Using metatranscriptomics, we identified the existence of two distinct molecular signatures of lethal COVID-19. The dominant ‘classical’ signature (n=23) showed upregulation of the unfolded protein response, steroid biosynthesis and complement activation, supported by massive metabolic reprogramming leading to characteristic lung damage. The rarer signature (n=8) that potentially represents ‘cytokine release syndrome’ (CRS) showed upregulation of cytokines such as IL1 and CCL19, but absence of complement activation. We found that a majority of patients cleared SARS-CoV-2 infection, but they suffered from acute dysbiosis with characteristic enrichment of opportunistic pathogens such as Staphylococcus cohnii in ‘classical’ patients and Pasteurella multocida in CRS patients. Our results suggest two distinct models of lung pathology in severe COVID-19 patients, which can be identified through complement activation, presence of specific cytokines and characteristic microbiome. These findings can be used to design personalized therapy using in silico identified drug molecules or in mitigating specific secondary infections.
UR - http://www.scopus.com/inward/record.url?scp=85131701451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131701451&partnerID=8YFLogxK
U2 - 10.1242/dmm.049572
DO - 10.1242/dmm.049572
M3 - Article
C2 - 35438176
AN - SCOPUS:85131701451
SN - 1754-8403
VL - 15
JO - DMM Disease Models and Mechanisms
JF - DMM Disease Models and Mechanisms
IS - 5
M1 - 049572
ER -